tiprankstipranks
Trending News
More News >
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
US Market

Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

Compare
1,240 Followers
See the Price Targets and Ratings of:

MDGL Analyst Ratings

Strong Buy
12Ratings
Strong Buy
10 Buy
1 Hold
1 Sell
Based on 12 analysts giving stock ratings to
Madrigal
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MDGL Stock 12 Month Forecast

Average Price Target

$416.55
▲(46.46%Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $416.55 with a high forecast of $475.00 and a low forecast of $248.00. The average price target represents a 46.46% change from the last price of $284.41.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"208":"$208","275":"$275","342":"$342","409":"$409","476":"$476"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$475.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":416.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$416.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":248,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$248.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[208,275,342,409,476],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,327.7,339.03076923076924,350.36153846153843,361.6923076923077,373.0230769230769,384.3538461538461,395.68461538461537,407.0153846153846,418.3461538461538,429.67692307692306,441.0076923076923,452.3384615384615,463.66923076923075,{"y":475,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,327.7,334.5346153846154,341.36923076923074,348.20384615384614,355.03846153846155,361.87307692307695,368.7076923076923,375.5423076923077,382.37692307692305,389.21153846153845,396.04615384615386,402.88076923076926,409.7153846153846,{"y":416.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,327.7,321.5692307692308,315.4384615384615,309.3076923076923,303.17692307692306,297.04615384615386,290.9153846153846,284.7846153846154,278.65384615384613,272.5230769230769,266.39230769230767,260.26153846153846,254.13076923076923,{"y":248,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":255.74,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.59,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":236.16,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":279.31,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.48,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.33,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":319.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":334.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":341.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":323.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$475.00Average Price Target$416.55Lowest Price Target$248.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on MDGL
Edward NashCanaccord Genuity
Canaccord Genuity
$420
Buy
47.67%
Upside
Reiterated
05/13/25
Promising Phase III Trial Results Support Buy Rating for Madrigal Pharmaceuticals
Bank of America Securities Analyst forecast on MDGL
Jason ZemanskyBank of America Securities
Bank of America Securities
$248
Sell
-12.80%
Downside
Reiterated
05/13/25
Uncertainties and Data Gaps Lead to Sell Rating for Madrigal Pharmaceuticals' Rezdiffra
Citi
$469$456
Buy
60.33%
Upside
Reiterated
05/13/25
Citi reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)Citi analyst David Lebowitz reiterated a Buy rating and $456.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)
TD Cowen Analyst forecast on MDGL
Ritu BaralTD Cowen
TD Cowen
$390
Buy
37.13%
Upside
Reiterated
05/12/25
Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Immunocore Holdings (NASDAQ: IMCR) and Madrigal Pharmaceuticals (NASDAQ: MDGL)
Evercore ISI Analyst forecast on MDGL
Liisa BaykoEvercore ISI
Evercore ISI
$392
Buy
37.83%
Upside
Reiterated
05/02/25
Evercore ISI Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
UBS
$441$458
Buy
61.04%
Upside
Reiterated
05/02/25
Madrigal Pharmaceuticals price target raised to $458 from $441 at UBSMadrigal Pharmaceuticals price target raised to $458 from $441 at UBS
B.Riley Financial Analyst forecast on MDGL
Mayank MamtaniB.Riley Financial
B.Riley Financial
$422$460
Buy
61.74%
Upside
Reiterated
05/02/25
Analysts Are Bullish on These Healthcare Stocks: Cerus (CERS), Madrigal Pharmaceuticals (MDGL)
Leerink Partners Analyst forecast on MDGL
Thomas SmithLeerink Partners
Leerink Partners
$415
Buy
45.92%
Upside
Reiterated
05/01/25
Madrigal Pharmaceuticals: Strong Market Performance and Growth Potential with Rezdiffra Leading the NASH Market
Citizens JMP Analyst forecast on MDGL
Jonathan WollebenCitizens JMP
Citizens JMP
$443$470
Buy
65.25%
Upside
Reiterated
05/01/25
JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
Cantor Fitzgerald Analyst forecast on MDGL
Prakhar AgrawalCantor Fitzgerald
Cantor Fitzgerald
Hold
Reiterated
04/29/25
Cantor Fitzgerald reiterates Neutral Rating on Madrigal Pharmaceuticals (MDGL)Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).
Oppenheimer Analyst forecast on MDGL
Jay OlsonOppenheimer
Oppenheimer
$475
Buy
67.01%
Upside
Reiterated
04/27/25
Madrigal Pharmaceuticals' Rezdiffra: A Promising First-Mover in MASH Treatment with Strong Growth Potential
Jefferies Analyst forecast on MDGL
Akash TewariJefferies
Jefferies
$398
Buy
39.94%
Upside
Reiterated
04/22/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on MDGL
Ed ArceH.C. Wainwright
H.C. Wainwright
$400$405
Buy
42.40%
Upside
Reiterated
02/27/25
Madrigal price target raised to $405 from $400 at H.C. WainwrightMadrigal price target raised to $405 from $400 at H.C. Wainwright
Goldman Sachs Analyst forecast on MDGL
Andrea NewkirkGoldman Sachs
Goldman Sachs
$539
Buy
89.52%
Upside
Reiterated
02/26/25
Piper Sandler Analyst forecast on MDGL
Yasmeen RahimiPiper Sandler
Piper Sandler
$336$400
Buy
40.64%
Upside
Reiterated
02/14/25
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Piper Sandler
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on MDGL
Edward NashCanaccord Genuity
Canaccord Genuity
$420
Buy
47.67%
Upside
Reiterated
05/13/25
Promising Phase III Trial Results Support Buy Rating for Madrigal Pharmaceuticals
Bank of America Securities Analyst forecast on MDGL
Jason ZemanskyBank of America Securities
Bank of America Securities
$248
Sell
-12.80%
Downside
Reiterated
05/13/25
Uncertainties and Data Gaps Lead to Sell Rating for Madrigal Pharmaceuticals' Rezdiffra
Citi
$469$456
Buy
60.33%
Upside
Reiterated
05/13/25
Citi reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)Citi analyst David Lebowitz reiterated a Buy rating and $456.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL)
TD Cowen Analyst forecast on MDGL
Ritu BaralTD Cowen
TD Cowen
$390
Buy
37.13%
Upside
Reiterated
05/12/25
Analysts Offer Insights on Healthcare Companies: BeiGene (NASDAQ: ONC), Immunocore Holdings (NASDAQ: IMCR) and Madrigal Pharmaceuticals (NASDAQ: MDGL)
Evercore ISI Analyst forecast on MDGL
Liisa BaykoEvercore ISI
Evercore ISI
$392
Buy
37.83%
Upside
Reiterated
05/02/25
Evercore ISI Keeps Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
UBS
$441$458
Buy
61.04%
Upside
Reiterated
05/02/25
Madrigal Pharmaceuticals price target raised to $458 from $441 at UBSMadrigal Pharmaceuticals price target raised to $458 from $441 at UBS
B.Riley Financial Analyst forecast on MDGL
Mayank MamtaniB.Riley Financial
B.Riley Financial
$422$460
Buy
61.74%
Upside
Reiterated
05/02/25
Analysts Are Bullish on These Healthcare Stocks: Cerus (CERS), Madrigal Pharmaceuticals (MDGL)
Leerink Partners Analyst forecast on MDGL
Thomas SmithLeerink Partners
Leerink Partners
$415
Buy
45.92%
Upside
Reiterated
05/01/25
Madrigal Pharmaceuticals: Strong Market Performance and Growth Potential with Rezdiffra Leading the NASH Market
Citizens JMP Analyst forecast on MDGL
Jonathan WollebenCitizens JMP
Citizens JMP
$443$470
Buy
65.25%
Upside
Reiterated
05/01/25
JMP Securities Reaffirms Their Buy Rating on Madrigal Pharmaceuticals (MDGL)
Cantor Fitzgerald Analyst forecast on MDGL
Prakhar AgrawalCantor Fitzgerald
Cantor Fitzgerald
Hold
Reiterated
04/29/25
Cantor Fitzgerald reiterates Neutral Rating on Madrigal Pharmaceuticals (MDGL)Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Neutral rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).
Oppenheimer Analyst forecast on MDGL
Jay OlsonOppenheimer
Oppenheimer
$475
Buy
67.01%
Upside
Reiterated
04/27/25
Madrigal Pharmaceuticals' Rezdiffra: A Promising First-Mover in MASH Treatment with Strong Growth Potential
Jefferies Analyst forecast on MDGL
Akash TewariJefferies
Jefferies
$398
Buy
39.94%
Upside
Reiterated
04/22/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on MDGL
Ed ArceH.C. Wainwright
H.C. Wainwright
$400$405
Buy
42.40%
Upside
Reiterated
02/27/25
Madrigal price target raised to $405 from $400 at H.C. WainwrightMadrigal price target raised to $405 from $400 at H.C. Wainwright
Goldman Sachs Analyst forecast on MDGL
Andrea NewkirkGoldman Sachs
Goldman Sachs
$539
Buy
89.52%
Upside
Reiterated
02/26/25
Piper Sandler Analyst forecast on MDGL
Yasmeen RahimiPiper Sandler
Piper Sandler
$336$400
Buy
40.64%
Upside
Reiterated
02/14/25
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Piper Sandler
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Madrigal Pharmaceuticals

1 Month
xxx
Success Rate
10/14 ratings generated profit
71%
Average Return
+31.04%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +31.04% per trade.
3 Months
xxx
Success Rate
11/14 ratings generated profit
79%
Average Return
+14.96%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +14.96% per trade.
1 Year
Ed ArceH.C. Wainwright
Success Rate
11/14 ratings generated profit
79%
Average Return
+80.62%
reiterated a buy rating 3 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +80.62% per trade.
2 Years
xxx
Success Rate
13/14 ratings generated profit
93%
Average Return
+90.17%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +90.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDGL Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
1
2
2
1
1
Buy
21
25
25
16
14
Hold
5
2
2
1
1
Sell
3
3
3
1
3
Strong Sell
2
2
2
0
0
total
32
34
34
19
19
In the current month, MDGL has received 15 Buy Ratings, 1 Hold Ratings, and 3 Sell Ratings. MDGL average Analyst price target in the past 3 months is 416.55.
Each month's total comprises the sum of three months' worth of ratings.

MDGL Financial Forecast

MDGL Earnings Forecast

Next quarter’s earnings estimate for MDGL is -$3.49 with a range of -$5.15 to -$1.99. The previous quarter’s EPS was -$3.32. MDGL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year MDGL has Outperformed its overall industry.
Next quarter’s earnings estimate for MDGL is -$3.49 with a range of -$5.15 to -$1.99. The previous quarter’s EPS was -$3.32. MDGL beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year MDGL has Outperformed its overall industry.

MDGL Sales Forecast

Next quarter’s sales forecast for MDGL is $156.24M with a range of $128.00M to $174.50M. The previous quarter’s sales results were $137.25M. MDGL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year MDGL has Outperformed its overall industry.
Next quarter’s sales forecast for MDGL is $156.24M with a range of $128.00M to $174.50M. The previous quarter’s sales results were $137.25M. MDGL beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year MDGL has Outperformed its overall industry.

MDGL Stock Forecast FAQ

What is MDGL’s average 12-month price target, according to analysts?
Based on analyst ratings, Madrigal Pharmaceuticals Inc’s 12-month average price target is 416.55.
    What is MDGL’s upside potential, based on the analysts’ average price target?
    Madrigal Pharmaceuticals Inc has 46.46% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MDGL a Buy, Sell or Hold?
          Madrigal Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Madrigal Pharmaceuticals Inc’s price target?
            The average price target for Madrigal Pharmaceuticals Inc is 416.55. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $475.00 ,the lowest forecast is $248.00. The average price target represents 46.46% Increase from the current price of $284.41.
              What do analysts say about Madrigal Pharmaceuticals Inc?
              Madrigal Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of MDGL?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis